Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit
May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK
A heterogeneity is seen in the benefit of empagliflozin in patients with HF 0:21
Proposed mechanism of benefit before the EMPA-REG Outcome trial 1:14
The surprising results have changed ideas on the mechanism of empagliflozin 2:51
Is the proposed mechanism just a diuretic effect or due to lowering blood pressure? 7:54
Patients with diabetes have higher HF risk 9:44
Emerging concept on the mechanism of benefit of SGLT2 inhibition. 10:40